Amgen Inc (AMGN)

$338.59 -6.09 (-1.77%)
Market Cap 184.10B
Revenue (ttm) 33.42B
Net Income (ttm) 4.09B
EPS (ttm) N/A
PE Ratio 15.68
Forward PE 15.70
Profit Margin 12.24%
Debt to Equity Ratio 5.67
Volume 4,037,600
Avg Vol 2,811,736
Day's Range N/A - N/A
Shares Out 538.48M
Stochastic %K 64%
Beta 0.45
Analysts Sell
Price Target $336.29

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 805 447 1000
Fax: 805 447 1010
Address:
One Amgen Center Drive, Thousand Oaks, United States
Estimize
Estimize Feb. 3 at 11:28 PM
$AMGN reported 5.29 EPS and 9,866 revenue for Q4. http://www.estimize.com/intro/amgn?chart=historical&metric_name=eps&utm_content=AMGN&utm_
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 3 at 10:33 PM
$AMGN
0 · Reply
CatCapital_ai
CatCapital_ai Feb. 3 at 9:18 PM
$AMGN Earnings - Q4/2025 Revenue: $9.87B ✅ vs. $9.37B est. EPS: $2.45 ❌ vs. $5.12 est. Amgen posts a strong 2025 showing with double-digit growth across its portfolio and clear momentum into 2026. GAAP earnings per share jumped sharply in Q4 and for the year, while non-GAAP EPS was roughly flat in Q4 and higher for the year. For 2026, the company expects net selling price to decline by roughly mid single-digits, updates on key programs (including MariTide, UPLIZNA and TEZSPIRE) and confirms it will terminate the rocatinlimab collaboration with Kyowa Kirin, subject to Hart-Scott-Rodino review, while noting the FDA asked ChemoCentryx to withdraw TAVNEOS but Amgen does not intend to withdraw and is evaluating next steps.
0 · Reply
howardlindzon
howardlindzon Feb. 3 at 9:09 PM
$AMGN somebody doing well
1 · Reply
JuggernautRaider
JuggernautRaider Feb. 3 at 9:09 PM
$AMGN has been crushing it lately in the big pharma space 💪
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 3 at 9:09 PM
$AMGN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $2.47 up 111.11% YoY • Reported revenue of $9.87B up 8.58% YoY • For the full year 2026, Amgen expects total revenues in the range of $37.0 billion to $38.4 billion, with GAAP EPS between $15.45 and $16.94, and non-GAAP EPS from $21.60 to $23.00.
0 · Reply
ARMRreport
ARMRreport Feb. 3 at 9:06 PM
$AMGN beats eps estimates 5.29 vs 4.75 sees 15.45-16.94 FY 2026 above est 13.53
0 · Reply
smartkarma
smartkarma Feb. 3 at 9:03 PM
🚨 BREAKING: AMGEN 4Q ADJ EPS $5.29, EST. $4.71 $AMGN
0 · Reply
DonCorleone77
DonCorleone77 Feb. 3 at 7:37 PM
$AMGN Amgen options imply 3.4% move in share price post-earnings Pre-earnings options volume in Amgen is normal with puts leading calls 3:2. Implied volatility suggests the market is anticipating a move near 3.4%, or $11.76, after results are released. Median move over the past eight quarters is 5.8%.
0 · Reply
DonCorleone77
DonCorleone77 Feb. 3 at 7:29 PM
$AMD $AMGN $CMG $LITE $SMCI Some notable companies reporting after the market close, with earnings consensus estimates:** - AMD (AMD), consensus $1.32 - Amgen (AMGN), consensus $4.76 - Chubb (CB), consensus $6.78 - Modelez (MDLZ), consensus 70c - Electronic Arts (EA), consensus $1.48 - Chipotle (CMG), consensus 24c - Take-Two (TTWO), consensus (-39c) - Prudential (PRU), consensus $3.36 - Lumentum (LITE), consensus $1.41 - Super Micro (SMCI), consensus 49c - Clorox (CLX), consensus $1.43 - Skyworks (SWKS), consensus $1.40 - Intapp (INTA), consensus 26c
0 · Reply
Latest News on AMGN
Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost

Feb 3, 2026, 4:58 PM EST - 2 hours ago

Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost

Amgen quarterly results beat Street estimates on higher sales, lower tax rate

Feb 3, 2026, 4:05 PM EST - 3 hours ago

Amgen quarterly results beat Street estimates on higher sales, lower tax rate

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Feb 3, 2026, 4:01 PM EST - 3 hours ago

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 6 hours ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT GPCR LLY NVO PFE VKTX

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

Jan 30, 2026, 1:09 PM EST - 4 days ago

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Jan 28, 2026, 4:01 PM EST - 6 days ago

AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential

Jan 22, 2026, 11:15 AM EST - 12 days ago

Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

Jan 20, 2026, 11:34 AM EST - 14 days ago

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing

Jan 15, 2026, 4:40 PM EST - 19 days ago

Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Jan 14, 2026, 12:36 PM EST - 20 days ago

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

Jan 13, 2026, 7:55 PM EST - 20 days ago

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

Jan 13, 2026, 7:51 PM EST - 20 days ago

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

Amgen CEO says weight loss drug can address 'patient persistence issue'

Jan 13, 2026, 6:54 PM EST - 21 days ago

Amgen CEO says weight loss drug can address 'patient persistence issue'

Ro partners with Amgen to study barriers to obesity care, GLP-1 access

Jan 13, 2026, 10:22 AM EST - 21 days ago

Ro partners with Amgen to study barriers to obesity care, GLP-1 access

Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:16 PM EST - 21 days ago

Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Amgen says MariTide helped trial patients maintain weight loss

Jan 12, 2026, 7:42 PM EST - 21 days ago

Amgen says MariTide helped trial patients maintain weight loss

Amgen to announce data on obesity drug MariTide at healthcare conference

Jan 12, 2026, 6:46 PM EST - 22 days ago

Amgen to announce data on obesity drug MariTide at healthcare conference

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

Jan 11, 2026, 7:40 AM EST - 23 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

CVX HD JNJ KO MRK NKE PG

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

Jan 10, 2026, 9:52 AM EST - 24 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

CRM DIS HD HON JNJ KO MRK

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 25 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AZN BMY LLY MRK NVO PFE

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Jan 7, 2026, 4:01 PM EST - 27 days ago

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

Jan 7, 2026, 1:45 PM EST - 27 days ago

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

Jan 6, 2026, 9:00 AM EST - 4 weeks ago

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

Jan 2, 2026, 5:06 PM EST - 4 weeks ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

CVX HD JNJ KO MRK NKE PG

These three ‘Dogs of the Dow' stocks are must-own for 2026

Dec 31, 2025, 12:12 PM EST - 4 weeks ago

These three ‘Dogs of the Dow' stocks are must-own for 2026

HD VZ

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

Dec 26, 2025, 10:35 PM EST - 5 weeks ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM ABT AVGO BCPC BEN

Can Amgen Sustain Its Rally In 2026

Dec 26, 2025, 1:03 PM EST - 5 weeks ago

Can Amgen Sustain Its Rally In 2026

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 6 weeks ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY ARGX AZN IBB

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

Dec 19, 2025, 4:09 PM EST - 6 weeks ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK GILD NVS SNY

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

Dec 19, 2025, 3:14 PM EST - 6 weeks ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

BMY GILD GSK MRK NVS SNY

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Dec 19, 2025, 2:34 PM EST - 6 weeks ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

BMY GILD GSK MRK NVS SNY

AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

Dec 19, 2025, 2:23 PM EST - 6 weeks ago

AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 6 weeks ago

Trump to announce new drug-pricing deals later today

ABBV AZN BMY GILD LLY MRK NVO

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 6 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AZN BMY LLY NVS PFE

FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease

Dec 12, 2025, 12:43 PM EST - 7 weeks ago

FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease

FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS

Dec 11, 2025, 6:09 PM EST - 7 weeks ago

FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND

Dec 9, 2025, 4:01 PM EST - 2 months ago

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND

Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 5:23 PM EST - 2 months ago

Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 5:13 PM EST - 2 months ago

Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 2 months ago

Dogs Of The Dow Continue Outperforming Broader Market

DIA JNJ MAGS SPY

AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE

Nov 24, 2025, 4:10 PM EST - 2 months ago

AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE

Nov 24, 2025, 4:00 PM EST - 2 months ago

AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

Nov 20, 2025, 11:17 AM EST - 2 months ago

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

BMY GILD IVV MRK PFE SPY VOO

FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nov 19, 2025, 4:01 PM EST - 2 months ago

FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AZN BIIB GILD GSK JNJ LLY

Trade Tracker: Bill Baruch buys more Amgen

Nov 13, 2025, 1:54 PM EST - 2 months ago

Trade Tracker: Bill Baruch buys more Amgen

Cramer's Stop Trading: Amgen

Nov 13, 2025, 10:30 AM EST - 2 months ago

Cramer's Stop Trading: Amgen

There Are Non-AI Stocks Worth Buying. Start With This List.

Nov 12, 2025, 2:54 PM EST - 2 months ago

There Are Non-AI Stocks Worth Buying. Start With This List.

CHD DG DIS VIK

Amgen CEO talks trial results of cardiac drug Repatha

Nov 10, 2025, 7:40 PM EST - 3 months ago

Amgen CEO talks trial results of cardiac drug Repatha

CEO of drugmaker Amgen talks new results from cholesterol drug trial

Nov 10, 2025, 6:39 PM EST - 3 months ago

CEO of drugmaker Amgen talks new results from cholesterol drug trial

Estimize
Estimize Feb. 3 at 11:28 PM
$AMGN reported 5.29 EPS and 9,866 revenue for Q4. http://www.estimize.com/intro/amgn?chart=historical&metric_name=eps&utm_content=AMGN&utm_
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 3 at 10:33 PM
$AMGN
0 · Reply
CatCapital_ai
CatCapital_ai Feb. 3 at 9:18 PM
$AMGN Earnings - Q4/2025 Revenue: $9.87B ✅ vs. $9.37B est. EPS: $2.45 ❌ vs. $5.12 est. Amgen posts a strong 2025 showing with double-digit growth across its portfolio and clear momentum into 2026. GAAP earnings per share jumped sharply in Q4 and for the year, while non-GAAP EPS was roughly flat in Q4 and higher for the year. For 2026, the company expects net selling price to decline by roughly mid single-digits, updates on key programs (including MariTide, UPLIZNA and TEZSPIRE) and confirms it will terminate the rocatinlimab collaboration with Kyowa Kirin, subject to Hart-Scott-Rodino review, while noting the FDA asked ChemoCentryx to withdraw TAVNEOS but Amgen does not intend to withdraw and is evaluating next steps.
0 · Reply
howardlindzon
howardlindzon Feb. 3 at 9:09 PM
$AMGN somebody doing well
1 · Reply
JuggernautRaider
JuggernautRaider Feb. 3 at 9:09 PM
$AMGN has been crushing it lately in the big pharma space 💪
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 3 at 9:09 PM
$AMGN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $2.47 up 111.11% YoY • Reported revenue of $9.87B up 8.58% YoY • For the full year 2026, Amgen expects total revenues in the range of $37.0 billion to $38.4 billion, with GAAP EPS between $15.45 and $16.94, and non-GAAP EPS from $21.60 to $23.00.
0 · Reply
ARMRreport
ARMRreport Feb. 3 at 9:06 PM
$AMGN beats eps estimates 5.29 vs 4.75 sees 15.45-16.94 FY 2026 above est 13.53
0 · Reply
smartkarma
smartkarma Feb. 3 at 9:03 PM
🚨 BREAKING: AMGEN 4Q ADJ EPS $5.29, EST. $4.71 $AMGN
0 · Reply
DonCorleone77
DonCorleone77 Feb. 3 at 7:37 PM
$AMGN Amgen options imply 3.4% move in share price post-earnings Pre-earnings options volume in Amgen is normal with puts leading calls 3:2. Implied volatility suggests the market is anticipating a move near 3.4%, or $11.76, after results are released. Median move over the past eight quarters is 5.8%.
0 · Reply
DonCorleone77
DonCorleone77 Feb. 3 at 7:29 PM
$AMD $AMGN $CMG $LITE $SMCI Some notable companies reporting after the market close, with earnings consensus estimates:** - AMD (AMD), consensus $1.32 - Amgen (AMGN), consensus $4.76 - Chubb (CB), consensus $6.78 - Modelez (MDLZ), consensus 70c - Electronic Arts (EA), consensus $1.48 - Chipotle (CMG), consensus 24c - Take-Two (TTWO), consensus (-39c) - Prudential (PRU), consensus $3.36 - Lumentum (LITE), consensus $1.41 - Super Micro (SMCI), consensus 49c - Clorox (CLX), consensus $1.43 - Skyworks (SWKS), consensus $1.40 - Intapp (INTA), consensus 26c
0 · Reply
inspector_gadget86
inspector_gadget86 Feb. 3 at 5:41 PM
$AMGN $LLY $NVO $OZEM unexpectedly warning that fiscal 2026 sales will be hurt by lower drug prices in the U.S. even as it anticipates more patients will use its popular GLP-1 drug.
0 · Reply
BixbyKnolls
BixbyKnolls Feb. 3 at 4:58 PM
$IBRX Again, $MRK , $AMGN .. other big pharma need $IBRX to make their drugs work better..extend their patent cliffs.
0 · Reply
Estimize
Estimize Feb. 3 at 4:00 PM
$AMGN reports after the close, Estimize Consensus +0.24 EPS and +115.41M Revs compared to WS http://www.estimize.com/amgn/fq4-2025?utm_cont
0 · Reply
DefenseMania
DefenseMania Feb. 3 at 12:28 PM
$AMGN Oh noooooo 😂😂😂 https://finance.yahoo.com/news/jim-cramer-amgen-biotech-really-122406856.html
0 · Reply
MargieAdams1042
MargieAdams1042 Feb. 3 at 6:09 AM
$DIS $AMGN Media and biotech
0 · Reply
parcha
parcha Feb. 3 at 12:59 AM
Tuesday's stock stories: What’s likely to move the market in the next session $MRK $PFE $AMGN Merck, Pfizer, Amgen All three big health-care stocks report Tuesday morning. Merck has gained about 32% in the past three months. The stock hit a new high on Monday. Pfizer has advanced 8% over the past three months. The stock is off 4% from the October high. Amgen has added 15.5% in the past three months. Shares are down 2.4% from last week’s high. https://www.cnbc.com/2026/02/02/tuesdays-big-stock-stories-whats-likely-to-move-the-market.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
dogDazeSummer
dogDazeSummer Feb. 2 at 9:04 PM
$IFRX $AMGN Holy smokes —-avacopan under negative review by EMA. Bad boys, bad boys, whatcha gonna do !? Vilo is the answer, plus doesn’t have that filthy loves tox issue. Perhaps Amgen should drop $4B on Inflarx vs sketchy ccxi https://www.ema.europa.eu/en/news/ema-starts-review-tavneos-medicine-rare-autoimmune-diseases-gpa-mpa
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 10:36 AM
$AMGN RSI: 67.79, MACD: 4.6510 Vol: 9.42, MA20: 335.51, MA50: 333.01 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PhoenixHedge
PhoenixHedge Jan. 30 at 3:33 PM
$AMGN $NKTR $SNY how’s that working out?
1 · Reply
Sunny3999
Sunny3999 Jan. 30 at 1:55 PM
$PMN before news of $175 million I wrote this will be a 10bagger $AMGN $GILD $LLY $REGN
0 · Reply
masonat
masonat Jan. 30 at 1:43 PM
$NKTR First the $SNY amlitelimab news, now $AMGN is walking away from rocatinlimab. Atopic derm market is wide open outside of Dupixent and Dupi me toos.
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 1:19 PM
$PMN Wow news $175 million private placement https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $AMGN $GILD $LLY $REGN
0 · Reply